SOURCE: CannaPharmaRx, Inc.

CannaPharmaRx, Inc. Logo

April 21, 2015 08:58 ET

CannaPharmaRx, Inc. Engages Drinker Biddle & Reath LLP as Legal Counsel

CARNEYS POINT, NJ--(Marketwired - April 21, 2015) - CannaPharmaRx, Inc. (OTCQB: CPMD), an early stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery, is pleased to announce that it has recently engaged Drinker Biddle & Reath LLP to serve as primary counsel on all of its corporate and securities matters.

Mr. Gerry Crocker, CannaPharmaRx's CEO, commented, "We are excited to work with a law firm with the national stature and presence of a firm like Drinker Biddle. They have been actively involved in the completion of our pending merger of our Colorado subsidiary, the final step in our company's formation contemplated in 2014, and all other legal matters. We look forward to a long and productive relationship with Drinker Biddle." 

About CannaPharmaRx, Inc.
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed system of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • Contact:

    Investor Relations for Viridian Capital & Research:
    Michael Swartz
    Viridian Capital & Research, LLC

    Investor Relations for CannaPharmaRx:
    Bridamary Rosario